Document is current
Any future updates will be listed below
-
Authors
Stenmark Tullberg, Axel
Thurfjell, Viktoria
Kovács, Anikó
Micke, Patrick
Moustakas, Aristidis
Killander, Fredrika
Niméus, Emma
Holmberg, Erik
Karlsson, Per
Strell, Carina
-
Funding
Funding for this research was provided by:
Bröstcancerförbundet, Sweden (FM 2023; FM2024-0017)
Vetenskapsrådet (2022-01151)
Selanders Stiftelse, Sweden
Cancerfonden (2019/0081, 21 1749Pj)
Stiftelsen Konung Gustaf V:s Jubileumsfond (2019:248)
Trond Mohn stiftelse (TMS2022STG01)
Uppsala University
- License Information
-
More Information
Article History
Received: 3 March 2025
Accepted: 20 May 2025
First Online: 9 June 2025
Declarations
:
: AST, PK, EH research contract with PFS Genomics; AST, EH, PK, CS research contracts with Prelude Dx as well as founders of TECKNET AB. VT, AK, AM, PM, FK, EN no disclosures.
: The study was approved by the Lund University Regional Ethical Review Board (approval numbers 2010/127 and 2015/548). The study was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments.
: Informed oral consent was obtained from all patients, which was determined appropriate and approved by the Ethical Review Board for the original trial and for this immunohistochemistry study.
